心房颤动心率控制:钙通道阻滞剂与β受体阻滞剂的比较
基于AFFIRM试验数据,比较非二氢吡啶类钙通道阻滞剂与β受体阻滞剂对非永久性房颤患者心率的影响。分析1112例基线窦律且使用上述药物者,随访中474例发生房颤。两药达到静息心率<110次/分的比例均为92%,但钙通道阻滞剂组窦律时心动过缓发生率显著更低(17% vs 32%)。校正后钙通道阻滞剂与窦律时心动过缓风险降低相关(OR 0.41, 95%CI 0.19-0.90)。
要点
- 钙通道阻滞剂与β受体阻滞剂在房颤时控制静息心率<110次/分的效果相当。
- 钙通道阻滞剂组窦律时心动过缓发生率显著低于β受体阻滞剂组(17% vs 32%)。
- 校正基线特征后,钙通道阻滞剂与窦律时心动过缓风险降低独立相关。
核心结论
- 在非永久性房颤患者中,使用钙通道阻滞剂控制心率者窦律时心动过缓发生率低于β受体阻滞剂。
研究设计与样本
- 基于AFFIRM随机对照试验数据的回顾性分析,共纳入4060例患者,其中1112例基线窦律且使用钙通道阻滞剂或β受体阻滞剂。
主要发现
- 随访中474例发生房颤且维持原心率控制药物,钙通道阻滞剂组218例(46%),β受体阻滞剂组256例(54%)。
- 房颤时静息心率<110次/分的达标率两组均为92%(p=1.00)。
- 窦律时心动过缓发生率钙通道阻滞剂组17%,β受体阻滞剂组32%(p<0.001)。
- 校正患者特征后,钙通道阻滞剂与窦律时心动过缓风险降低相关(OR 0.41, 95%CI 0.19-0.90)。
临床怎么用
- 对于非永久性房颤患者,选择钙通道阻滞剂而非β受体阻滞剂可能减少窦律时心动过缓的发生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate heart rate differences between non-dihydropyridine calcium channel blockers and beta-blockers in patients with non-permanent atrial fibrillation (AF). METHODS: Using data from 'A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation' (AFFIRM), where patients were randomised 1:1 rate or rhythm control, we compared the effect of rate control drugs on heart rate during AF as well as during sinus rhythm. Multivariable logistic regression was used to adjust for baseline characteristics. RESULTS: A total of 4060 patients were enrolled in the AFFIRM trial, mean age was 70±9 years, 39% were women. Out of the total, 1112 patients were in sinus rhythm at baseline and used either non-dihydropyridine channel blockers or beta-blockers. Of them, 474 had AF during follow-up while remaining on the same rate control drugs, 218 (46%) on calcium channel blockers and 256 (54%) on beta-blockers. Mean age of calcium channel blocker patients was 70±8 years and 68±8 for beta-blocker patients (p=0.003), 42% were women. A resting heart rate <110 beats per min during AF was achieved in 92% of patients using calcium channel blockers and 92% of patients using beta-blockers (p=1.00). Bradycardia during sinus rhythm occurred in 17% of patients using calcium channel blockers vs 32% using beta-blockers (p<0.001). After adjusting for patient characteristics, calcium channel blockers were associated with a reduction in bradycardia during sinus rhythm (OR 0.41, 95% CI 0.19 to 0.90). CONCLUSION: In patients with non-permanent AF, calcium channel blockers instituted for rate control were associated with less bradycardia during sinus rhythm compared with beta-blockers.
引用
- Koldenhof T, Van Gelder IC, Crijns HJ, et al. Rate control in atrial fibrillation, calcium channel blockers versus beta-blockers. Heart. 2023. PMID: 37433659. doi:10.1136/heartjnl-2023-322635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。